Jia Gao

Dr. Jia Gao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GNGilbert Nshogoza
Gilbert Nshogoza
YLYaqian Liu
Yaqian Liu
JGJia Gao
Jia Gao
MLMingqing Liu
Mingqing Liu
SMSayed Ala Moududee
Sayed Ala Moududee
KRKe Ruan
Ke Ruan
The TDP-43 is originally a nuclear protein but translocates to the cytoplasm in the pathological condition. TDP-43, as an RNA-binding protein, consists of two RNA Recognition Motifs (RRM1 and RRM2). RRMs are known to involve both protein-nucleotide and protein-protein interactions and mediate the formation of stress granules. Thus, they assist the entire TDP-43 protein with participating in neurodegenerative and cancer diseases. Consequently, they are potential therapeutic targets. Protein-observed and ligand-observed nuclear magnetic resonance (NMR) spectroscopy were used to uncover the small molecule inhibitors against the tandem RRM of TDP-43. We identified three hits weakly binding the tandem RRMs using the ligand-observed NMR fragment-based screening. The binding topology of these hits is then depicted by chemical shift perturbations (CSP) of the 15N-labeled tandem RRM and RRM2, respectively, and modeled by the CSP-guided High Ambiguity Driven biomolecular DOCKing (HADDOCK). These hits mainly bind to the RRM2 domain, which suggests the druggability of the RRM2 domain of TDP-43. These hits also facilitate further studies regarding the hit-to-lead evolution against the TDP-43 RRM domain.

Verified
Journal Article
Open access
PDF file
HTHeng Tang
Heng Tang
LWLei Wang
Lei Wang
SLShuju Li
Shuju Li
XWXiaoli Wei
Xiaoli Wei
MLMengqi Lv
Mengqi Lv
WXWeiping Xu
Weiping Xu
Melanoma differentiation-associated gene 9 (MDA-9) is a small adaptor protein with tandem PDZ domains that promotes tumor progression and metastasis in various human cancers. However, it is difficult to develop drug-like small molecules with high affinity due to the narrow groove of the PDZ domains of MDA-9. Herein, we identified four novel hits targeting the PDZ1 and PDZ2 domains of MDA-9, namely PI1A, PI1B, PI2A, and PI2B, using a protein-observed nuclear magnetic resonance (NMR) fragment screening method. We also solved the crystal structure of the MDA-9 PDZ1 domain in complex with PI1B and characterized the binding poses of PDZ1-PI1A and PDZ2-PI2A, guided by transferred paramagnetic relaxation enhancement. The protein–ligand interaction modes were then cross-validated by the mutagenesis of the MDA-9 PDZ domains. Competitive fluorescence polarization experiments demonstrated that PI1A and PI2A blocked the binding of natural substrates to the PDZ1 and PDZ2 domains, respectively. Furthermore, these inhibitors exhibited low cellular toxicity, but suppressed the migration of MDA-MB-231 breast carcinoma cells, which recapitulated the phenotype of MDA-9 knockdown. Our work has paved the way for the development of potent inhibitors using structure-guided fragment ligation in the future.

19 July 2024 in FEBS Letters
Verified
Journal Article
Closed access
XWXiaoli Wei
Xiaoli Wei
SLShuju Li
Shuju Li
ZLZihuan Li
Zihuan Li
LWLei Wang
Lei Wang
WFWeiwei Fan
Weiwei Fan
JGJia Gao
Jia Gao

1 August 2025 in Magnetic Resonance Letters
Verified
Journal Article
Open access
ZLZihuan Li
Zihuan Li
LWLei Wang
Lei Wang
JGJia Gao
Jia Gao
KRKe Ruan
Ke Ruan
Nuclear magnetic resonance (NMR) spectroscopy is an indispensable tool to probe weak protein-ligand interactions, which are key to the hit identification and hit-to-lead evolution in fragment-based drug discovery (FBDD). The integration of NMR technology in FBDD has facilitated the development of a diverse array of candidate compounds and FDA-approved drugs. Here, we summarized the rapid advancement and application of NMR techniques in contemporary China, which serves as a catalyst for the ongoing prosperousness of fragment-derived inhibitors against various targets.

26 June 2026 in Protein & Cell
Verified
Journal Article
Open access
YSYuexiao Song
Yuexiao Song
CSChangchun Shao
Changchun Shao
YZYiruo Zhang
Yiruo Zhang
MYMin Yang
Min Yang
YLYaqian Liu
Yaqian Liu
YDYingying Du
Yingying Du
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer remains a pressing clinical challenge. Liquid-liquid phase separation has emerged as a new mechanism of drug resistance, yet its role in EGFR-TKI resistance in lung cancer is largely unexplored. Herein, we prioritized Sequestosome 1 (SQSTM1/p62) as a key condensate by integrating proteomics data from EGFR-TKI resistance cell lines and clinical biopsy specimens, in which the cytoplasmic p62 condensate formation positively correlated with EGFR-TKI resistance. Domain mapping demonstrated that the PB1 and UBA domains of p62 were critical for promoting phase separation and reducing sensitivity to EGFR-TKI treatment, whereas S403 phosphorylation promoted p62 condensation and EGFR-TKI resistance. Further xenograft studies validated that reduction of p62 condensation restores EGFR-TKI sensitivity. Kinase enrichment and interaction assays identified TBK1 as an upstream regulator of p62 S403 phosphorylation to promote p62 condensation after pharmacological inhibition of EGFR. Notably, among the five compounds identified from a drug library screen that both disrupted p62 condensate formation and inhibited the viability of resistant cells, the highly selective TBK1 inhibitor GSK8612 stood out. GSK8612 inhibited p62 S403 phosphorylation and consequently, at subcytotoxic doses, synergized with EGFR-TKIs to suppress the viability of resistant cells and tumor growth in the xenograft mouse model. These findings propose TBK1-p62 axis links p62 condensate homeostasis to EGFR-TKI resistance as an underlying mechanism of action and an emerging strategy to resensitize EGFR-TKI treatment in resistant lung cancer.

8 November 2024 in ACS Chemical Biology
Verified
Journal Article
Closed access
FZFumei Zhong
Fumei Zhong
YZYu Zhou
Yu Zhou
MLMingqing Liu
Mingqing Liu
LWLei Wang
Lei Wang
FLFudong Li
Fudong Li
KRKe Ruan
Ke Ruan